You just read:

Quest PharmaTech Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

News provided by

Quest PharmaTech Inc.

Jan 22, 2013, 09:30 EST